- Journal of Health Sciences and Medicine
- Vol: 5 Issue: 1
- Pancreatic cancer treatment after FOLFIRINOX: prognostic importance of chemotherapy dose intensity a...
Pancreatic cancer treatment after FOLFIRINOX: prognostic importance of chemotherapy dose intensity and albumin/globulin ratio in second line
Authors : Özgen Ahmet Yildirim, Erkan Erdur
Pages : 156-160
Doi:10.32322/jhsm.1011658
View : 16 | Download : 5
Publication Date : 2022-01-17
Article Type : Research
Abstract :Aim: Pancreatic adenocarcinoma (PA) is the seventh most common cause of cancer-related mortality. Our primary endpoint of study was to determine the relationship between albumin/globulin ratio (AGR) and progression-free and overall survival (PFS and OS) in second-line treatment after FOLFIRINOX. Our secondary endpoint was to assess treatment side effects and the relationship of treatment dose intensity with treatment type and AGR. Material and Method: PA patients who followed-up between January 2014 and January 2021 were evaluated retrospectively. Age, gender, ECOG score and AGR recorded at the beginning of the second-line treatment. Thrombocytopenia, neutropenia, chemotherapy type, chemotherapy dose intensity, PFS and OS were recorded during the second-line treatment. Results: Median age 64 (44-80), 72 (70.6%) male, 102 metastatic PA patients were evaluated. 76 (74.5%) patients were ECOG 0-1, 26 (25.5%) patients were ECOG 2. Of these patients in the second step, 68 (66.7%) received single-agent gemcitabine and 34 (33.3%) received Nab-paclitaxel + gemcitabine treatment. Progression and exitus events occurred in all cases. Median PFS was 166.8 days in the AGR>1.2 group, it was 80.7 days in the AGR 1.2 group, it was 144 days in the AGR 1.2 group, it was 71.3% in the AGR<1.2 group (p=0.002). Conclusion: Even with palliative and advanced treatment, achieving a dose density close to 80% is a good prognostic indicator. AGR is a prognostic marker that remains effective in advanced stages of PA.Keywords : pancreatic cancer, dose intensity, albumin globulin ratio